You are here

Article Text

Article menu
Download PDFPDF
Letters
PostScript
Authors’ reply
  1. H-J Aubin1,
  2. A Bobak2,
  3. J R Britton3,
  4. C Oncken4,
  5. C B Billing, Jr5,
  6. J Gong5,
  7. K E Williams5,
  8. K R Reeves5
  1. 1
    Hôpital Emile Roux, Assistance Publique-Hopitaux de Paris, Limeil-Brévannes, France; Centre d’Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, Paris, France; Assistance Publique-Hôpitaux de Paris, Villejuif, France; INSERM, Paris, France
  2. 2
    Wandsworth Medical Centre, London, UK
  3. 3
    University of Nottingham, Nottingham, UK
  4. 4
    University of Connecticut Health Center, Farmington, Connecticut, USA
  5. 5
    Pfizer Global Research and Development, Groton, Connecticut, USA
  1. Dr H-J Aubin, Centre de Traitement des Addictions, Hôpital Emile Roux, F-94456 Limeil-Brévannes Cedex, France; henri-jean.aubin{at}erx.aphp.fr

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We recognise the relevance of showing long-term outcomes of smoking cessation therapies. However, many drug trials use end of treatment measures as primary outcomes.1 2 Given the high attrition rates during the follow-up phase, choosing long-term primary outcomes has a high impact on the numbers of subjects needed. It is noteworthy that the study cited by Hillman et al failed to show any significant difference between the efficacy of a nicotine patch and placebo at 6 and 12 months of follow-up.3

    We would like to acknowledge that the Russell standard includes …

    View Full Text

    Footnotes

    • Competing interests: H-JA has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from GlaxoSmithKline, Pierre-Fabre Sante, Sanofi-Aventis, Merck-Lipha and Pfizer. AB has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Pfizer. In the past 5 years JRB has received consultancy fees from Xenova and Novartis and his employing institution has received consultancy fees and honoraria on his behalf from Pfizer. CO has received honoraria and consulting fees from Pfizer; nicotine and placebo products for research studies at no cost from GlaxoSmithKline; and honoraria from Pri-Med and CME outfitters. CBB, JG, KEW and KRR are employees of Pfizer.